Longevity contest tracks who ages slowest
What if hundreds of people could simultaneously test who is best at rolling back their biological age? That is the premise behind a new initiative launching in early 2027.
NeuroAge Therapeutics has announced Younger 2027: a six-month competition in which participants are assessed on a comprehensive panel of biological aging markers, then choose their own six-month intervention before being retested. The organisers are collaborating with TruDiagnostic, Harvard FaceAge, and Vero Bioscience, with scientific input from researchers at MIT, Harvard, Yale, and Stanford.
The standard measurement package includes epigenetic clocks (measurements of chemical marks on DNA that reflect aging), a cognitive assessment, facial age via an AI model, and functional measures such as VO2 max and grip strength. Participants who opt for the extended package additionally receive two brain MRI scans, multiple protein-based aging clocks, and body composition via a DEXA scan. Some of those clocks are not yet publicly available.
Science or spectacle?
The competition format raises methodological questions that the organisers do not address. Participants choose their own interventions, there is no control group, and prizes are awarded based on absolute change in the composite score. That makes it difficult to determine after the fact what caused any changes observed. This is not a randomised trial; comparison with clinical science therefore has clear limits.
Nevertheless, the initiative has an interesting dimension: it collects standardised, multi-layered data from a large group of active longevity enthusiasts. That data could, if properly shared, prove useful for follow-up research. Whether that will actually happen is not stated.
Biological age as a competitive domain
Younger 2027 fits a broader trend in which biological aging clocks are being deployed outside pure science: by insurers, companies, and now in a competitive context. From a longevity standpoint, it is notable how quickly epigenetic clocks have shifted from laboratory instruments to consumer products. Whether the scores measured are genuinely clinically relevant for individual participants remains an open question.
Search terms: epigenetic aging clocks consumer research, biological age intervention measurement, multi-organ methylation clocks